Background: The Canadian Nosocomial Infection Surveillance Program (CNISP) is a collaborative effort of the Public Health Agency of Canada's Centre for Communicable Diseases and Infection Control, the National Microbiology Laboratory, and 54 largely university-affiliated tertiary care sentinel hospitals in 10 provinces across Canada.
Introduction
Since the initial use of antibiotics in the 1940s, resistant strains of bacteria have emerged. Increasingly however, antibiotic resistance is seen as a challenge in both clinical care and public health. Antibiotic resistance has spread around the world, affecting both human health and the food supply. The Public Health Agency of Canada (the Agency or PHAC) collects national data on antimicrobial resistant organisms in humans through the Canadian Nosocomial Infection Surveillance Program (CNISP). This is a collaborative effort of the Centre for Communicable Diseases and Infection Control, the National Microbiology Laboratory (NML) and sentinel hospitals across Canada that participate as members of the Canadian Hospital Epidemiology Committee, a subcommittee of the Association of Medical Microbiology and Infectious Disease Canada (AMMI). CNISP is intended to identify trends and inform infection prevention and control programs and policies across the country.
The CNISP surveillance reports are published on a regular basis. The objective of this paper is to provide a summary of antibiotic resistance rates of four key antibiotic resistant organisms in major hospitals across Canada: health care-associated Clostridium difficile infection (HA-CDI), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE), and carbapenem-resistant Enterobacteriaceae (CRE). This paper focuses on trends for both adult and children hospitalized in participating CNISP hospitals based on patient admissions per year. The most recent full CNISP report, Antimicrobial Resistant Organisms (ARO) Surveillance-Surveillance Report for Data from January 1 2007 to December 31 2012, is available online (1).
Methods

Data collection
Case definitions were agreed upon for each of the four organisms. Following a case identification in one of the participating hospitals, a standardized patient questionnaire was completed that included patient demographics, clinical information, previous hospitalization within the past 12 months, and site of positive culture. Data were then submitted electronically through a web-based information management system, the Canadian Network for Public Health Intelligence (CNPHI), to PHAC for further statistical analysis and storage. Participating hospitals also provided the Agency with the number of patient-admissions and the number of patients-days for the corresponding surveillance year. [Note: very slight differences in reported numbers occur in this paper compared to the online report due to recent updates from participating sites; where differences exist, CCDR should be taken as correct.] Standard National Healthcare Safety Network (NHSN) surveillance definitions that include both laboratory and clinical criteria were used to determine infection. (If there were no clinical signs, the patient was determined to be colonized; not infected.)
Laboratory analysis
Based on an agreed upon protocol for each organism, a sampling of isolates were sent to the National Microbiology Laboratory (NML) for molecular testing. The NML sent the laboratory results to PHAC through CNPHI as well. Both the laboratory results and data collected through the patient questionnaires were linked using a unique, anonymized patient identifier.
Data analysis
Data from both participating hospitals and the NML were extracted, validated, and statistically analyzed by PHAC staff. Infection rates per 1,000 patient admissions were calculated by dividing the number of cases over the total number of admissions per year multiplied by 1,000. Rates are calculated using only eligible data, that is to say only the hospitals that supplied both numerator (cases) and denominator (patient admissions) data are used to calculate the rates. For reporting purposes, and to ensure confidentiality, provinces were grouped into three regions: Western (British Columbia, Alberta, Saskatchewan, and Manitoba), Central (Ontario and Québec), and Eastern (Nova Scotia, New Brunswick, Prince Edward Island, and Newfoundland and Labrador). (Prince Edward Island began submitting data in 2011; the territories do not currently submit data.) Surveillance at participating hospitals is considered to be within the mandate of hospital infection prevention and control programs and does not constitute human research; therefore, no research ethics board approval was sought.
Results
Health care-associated Clostridium difficile
Clostridium difficile is the most common cause of infectious diarrhea and pseudomembranous colitis in hospitals and long-term care facilities in Canada (2). C. difficile causes a range of illness from no symptoms at all to a severe, life-threatening disease (3) . The population at risk of acquiring Clostridium difficile infection (CDI) includes the elderly, or people with certain antibiotics exposure, immunocompromising conditions or serious underlying disease. Only health-care associated cases of C. difficile are reported here as per the case definition (see box below).
A Case definition of hospital-acquired Clostridium difficile infection A A patient is identified as having Clostridium difficile infection (CDI) if the patient:
 has diarrhea or fever, abdominal pain and/or ileus, and a laboratory confirmation of a positive toxin assay or positive polymerase chain reaction (PCR) test for C.difficile;  has a diagnosis of pseudomembranes on sigmoidoscopy or colonoscopy or histological/ pathological diagnosis of CDI; or  is diagnosed with toxic megacolon (in adult patients only).
In addition, a patient is considered to have hospital-acquired Clostridium difficile infection (HA-CDI) if:
 the patient's CDI symptoms occur in the admitting hospital less than 72 hours after admission; or  CDI is seen in a patient who had been hospitalized in the admitting hospital and discharged within the previous four weeks.
In Canada, national rates of health care- Overall, the North American pulsed field type 1 (NAP 1) strain was the most dominant strain. Of the 2,497 submitted stool specimens, the NAP 1 strain was found in 1,059 (42.4%) specimens; 11.0% were NAP 4 strain type and 10.3% were NAP 2 (data not shown).
Methicillin-resistant Staphylococcus aureus (MRSA)
Staphylococcus aureus (S. aureus) typically colonizes the skin and mucosal surfaces of healthy humans. It can also cause wound, urine, skin and soft tissue infections, osteomyelitis, endocarditis, and bacteremia. S. aureus can be acquired in the community or in the hospital or other health care settings such as long-term care, dialysis, and rehabilitation facilities. S. aureus is particularly successful in becoming antibiotic resistant, explaining in part its high associated burden of disease worldwide (4). MRSA is a S. aureus that has become resistant to first line beta-lactam antibiotics such as methicillin, oxacillin, penicillin, and amoxicillin. Only health care-associated cases of Clostridium difficile are reported here as per the case definition (see box below).
Case definition of methicillin-resistant Staphylococcus aureus (MRSA) infection
• 
Vancomycin-resistant Enterococci (VRE)
VRE
Case definition of vancomycin-resistant Enterococci
Any inpatient from whom Enterococcus faecium or Enterococcus faecalis having a minimum inhibitory concentration of vancomycin of >8 ug/mL was isolated from a clinical specimen.
The rates of VRE have been low but rising with 0.08 VRE infections per 1,000 patient admissions in 2007, rising to 0.5 VRE infections per 1,000 admissions in 2012, with consistently higher rates in the Western region, slightly lower rates in the Central region, and the lowest rates in the Eastern region (Figure 3) . 
Carbapenem-resistant Enterobacteriaceae (CRE)
Gram-negative bacilli cause a variety of diseases, ranging from pneumonia to urinary tract infections, wound infections to septicemia. They typically occur in ill patients with exposure to acute and long-term care settings. Infections are commonly caused by species belonging to the Enterobacteriaceae family, such as Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloaca. These bacteria are often resistant to many commonly prescribed antibiotics, but typically remain susceptible to the carbapenem group of antimicrobials. There are currently no new antibiotics in development to combat bacteria resistant to carbapenems. The case definition of carbapenem-resistant Enterobacteriaceae has evolved over time (see box below).
Case definition of carbapenem-resistant Enterobacteriaceae isolates
From January 1, 2010, to August 31, 2010, any patient with an Enterobacteriaceae that exhibited a minimum inhibitory concentration (MIC) value ≥2 g/ml for any of three carbapenem antimicrobials (imipenem, meropenem, ertapenem); or a disk diffusion diameter ≤1mm was eligible for inclusion.
From September 1, 2010, to December 31, 2012, the MIC for ertapenem was decreased to ≥0.5 g/ml and a disk diffusion diameter for any carbapenem ≤22 mm was considered eligible for inclusion.
The rates of carbapenem-resistant Enterobacteriaceae (CRE) have been measured since 2010 and have been low and stable, with 0.11 infections per 1,000 patient admissions in 2010 and 0.14 infections per 1,000 admissions in 2012, with higher rates in the Western and Central regions and lower rates in the Eastern region (Figure 4) . 
Discussion
In Canada over the last few years, of the four antibiotic resistant organisms under surveillance, health care-associated Clostridium difficile and methicillin-resistant Staphylococcus aureus have been gradually decreasing; vancomycin-resistant Enterococci infections have been low but are rising; and carbapenemresistant Enterobacteriaceae infection remains low, with Western and Central rates consistently higher than Eastern rates.
Comparison of Canadian rates with international rates is difficult due to different definitions and analyses. For example, some countries report on MRSA bacteremia versus all types of MRSA. A number of countries report rates per 100,000 population, whereas these Canadian rates have been calculated using patient admissions to hospital. In addition, regional variation in rates is seen in countries and regions around the world. However, the overall trends seen in Canada are not dissimilar from trends observed elsewhere in the world.
Several limitations should be considered when interpreting the data presented here. First, the CNISP surveillance data is likely an underestimate as it does not represent the total number of inpatients in Canada with these infections. These data can only tell us about inpatients who have been tested and diagnosed, and not those who remain untested and undiagnosed. Cases identified in outpatient settings such as emergency departments and clinics are not captured by this surveillance system. Participating hospitals are not necessarily representative of all Canadian hospitals; for example, they tend to be large, tertiary acute care centres located in major cities. Antibiotic prescribing practices and implementation of infection prevention, and control measures may vary across hospitals, but because this surveillance system does not collect data regarding these factors, it is not possible to correlate them with the occurrence of these infections. And, as always, these results are subject to change as new data are made available. Antimicrobial resistance will continue to challenge the health of Canadians and of people around the world for some time to come. Surveillance will help document the progress we continue to make in curbing it. 
